Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai, China (mainland).
Department of Nuclear Medicine, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China (mainland).
Med Sci Monit. 2020 Feb 20;26:e920473. doi: 10.12659/MSM.920473.
BACKGROUND We investigated the relationship between the 18F-FDG PET/CT metabolic parameter SUVmax in primary hepatocellular carcinoma (HCC) and expression of von Hippel-Lindau (VHL), as well as its effect on HCC survival prognosis. MATERIAL AND METHODS We retrospectively analyzed data for 62 HCC patients who received 18F-FDG PET/CT before surgery at the First Affiliated Hospital of Bengbu Medical College from June 2013 to June 2018 (42 males, 20 females; median age 62 years). No treatment was performed prior to the examination. The relationship between preoperative 18F-FDG PET/CT metabolic parameters, clinical pathology, and disease prognosis was analyzed. RESULTS SUVmax was significantly different in varying HCC pathological grades, and with tumor length, lymph node metastasis, portal vein tumor thrombus, and distant metastasis (p<0.05). SUVmax was significantly higher in the shorter patient survival group (p<0.05). 18F-FDG uptake was correlated with expression of glucose transporter 1 and VHL in tumor tissues (correlation coefficients 0.476 and 0.565, respectively; both p<0.05). Negative expression of VHL suggested poor tumor differentiation and poor prognosis, but no correlation was observed with patient age, sex, tumor length, lymph node metastasis, or distant metastasis. The survival time of patients with low VHL expression was significantly shorter than that of patients with positive VHL expression (p=0.02). CONCLUSIONS VHL expression in primary HCC has a significant correlation with SUVmax, and negative VHL expression predicts a worse clinical prognosis.
我们研究了原发性肝细胞癌（HCC）中 18F-FDG PET/CT 代谢参数 SUVmax 与 von Hippel-Lindau（VHL）表达之间的关系，以及其对 HCC 生存预后的影响。
我们回顾性分析了 2013 年 6 月至 2018 年 6 月在蚌埠医学院第一附属医院接受 18F-FDG PET/CT 检查的 62 例 HCC 患者的数据（42 名男性，20 名女性；中位年龄 62 岁）。检查前未进行任何治疗。分析了术前 18F-FDG PET/CT 代谢参数与临床病理及疾病预后的关系。
SUVmax 在不同 HCC 病理分级、肿瘤长度、淋巴结转移、门静脉癌栓和远处转移中差异有统计学意义（p<0.05）。在患者生存时间较短的组中 SUVmax 明显较高（p<0.05）。18F-FDG 摄取与肿瘤组织中葡萄糖转运蛋白 1 和 VHL 的表达呈正相关（相关系数分别为 0.476 和 0.565，均 p<0.05）。VHL 阴性表达提示肿瘤分化不良、预后不良，但与患者年龄、性别、肿瘤长度、淋巴结转移或远处转移无关。VHL 表达阴性患者的生存时间明显短于 VHL 表达阳性患者（p=0.02）。
原发性 HCC 中 VHL 表达与 SUVmax 有显著相关性，VHL 表达阴性预示着更差的临床预后。
